Core Insights - Sofwave Medical Ltd reported record quarterly revenue of $21.1 million for Q3 2025, reflecting a 56% year-over-year growth, with a gross margin of 73.7% [1][5][6] - The company achieved a recurring revenue of $8.3 million in Q3 2025, marking a 55% increase year-over-year, which constitutes 40% of total revenue [1][5] - For the first nine months of 2025, Sofwave's revenue reached $58.7 million, a 42% year-over-year growth, with a gross margin of 75.1% [1][5][6] - Sofwave reported a net income of $1.4 million for the first nine months of 2025, a significant turnaround from a net loss of $3.8 million in the same period of the previous year [1][5][6] - The company has administered approximately 667,000 pulse treatments since commercialization and anticipates achieving net profitability by 2025 [1][8] Financial Highlights - Q3 2025 revenue was $21.1 million, up from $13.5 million in Q3 2024, with a gross profit of $15.5 million, a 53% increase year-over-year [5][6] - The first nine months of 2025 saw revenues of $58.7 million compared to $41.3 million in the same period of 2024, with a gross profit of $44.1 million, reflecting a 41% increase [5][6] - Positive cash flow of $2.5 million was generated in Q3 2025, compared to $0.2 million in the corresponding period of the previous year [5][6] Management Commentary - The CEO of Sofwave highlighted the exceptional performance in Q3 2025, driven by over 50% year-over-year growth in both capital equipment placements and recurring revenue, indicating strong demand from customers [4] - The Chairman emphasized the record revenue as a testament to the company's disruptive technology and the shift in the aesthetic market towards next-generation treatment solutions [4] - The company is positioned to expand further in the non-invasive medical aesthetics space, driven by the growing adoption of GLP-1 treatments [4]

Core Viewpoint - Sofwave Medical Ltd is actively participating in multiple investor conferences to showcase its innovative aesthetic medical devices and proprietary technology aimed at non-invasive treatments for skin conditions [1][2]. Company Overview - Sofwave Medical Ltd specializes in energy-based non-invasive aesthetic medical devices, focusing on wrinkle reduction, lifting, and cellulite treatment using its proprietary SUPERB™ technology [2]. - The SUPERB™ technology is FDA-cleared for improving facial lines and wrinkles, lifting the eyebrow, and enhancing skin laxity in various areas, including the upper arms and beneath the chin [2]. - The company's Pure Impact™ module utilizes EMS technology for muscle toning and is also FDA-cleared [2]. Upcoming Investor Conferences - Sofwave Medical will present at the following conferences: - Stifel 2025 Healthcare Conference on November 12, 2025, at 10:40 a.m. ET [1]. - Jefferies London Healthcare Conference on November 19, 2025, at 9:30 a.m. GMT [1]. - Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, at 9:30 a.m. ET [2].

Core Insights - Sofwave Medical Ltd is an emerging leader in energy-based non-invasive aesthetic medical devices [1] - The company will participate in the Jefferies Virtual Private MedTech Summit on October 1st, 2025, with CEO Louis Scafuri and CFO Assaf Korner representing the company [1] Company Overview - Sofwave Medical has developed a proprietary technology called SUPERB™ (Synchronous Ultrasound Parallel Beam) that is FDA-cleared for various aesthetic applications, including wrinkle reduction, eyebrow lifting, and improving skin laxity [2] - The company's Pure Impact™ module utilizes EMS technology and is also FDA-cleared for muscle toning [2] - Sofwave's products are designed to provide physicians with effective, safe, and user-friendly aesthetic solutions for their patients [2]

Company Overview - Sofwave Medical Ltd is an emerging leader in energy-based non-invasive aesthetic medical devices for practitioners worldwide [1] - The company has developed innovative technologies for wrinkle reduction, lifting, and cellulite treatment [2] Technology and Products - Sofwave's proprietary technology, SUPERB™ (Synchronous Ultrasound Parallel Beam), is FDA-cleared for improving facial lines, lifting eyebrows, and enhancing skin laxity in various areas [2] - The company's Pure Impact™ module utilizes 4th generation EMS technology, which is also FDA-cleared for muscle toning [2] Upcoming Events - The CEO Louis Scafuri and CFO Assaf Korner will participate in the 10th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference on August 11-12, 2025 [1]

Core Insights - Sofwave Medical Ltd reported record quarterly revenue of $21 million in Q2 2025, reflecting a 43% year-over-year growth, and expects to achieve operating break-even for the full year [3][4][5] - The company has a strong recurring revenue stream, with $9.2 million in Q2, representing a 53% year-over-year increase, and over 40% of total revenue coming from recurring sources [4][5][9] - Sofwave's innovative technology and FDA clearances are driving rapid adoption in the aesthetic medical device market, with over 600,000 treatments conducted since launch [3][8][9] Financial Highlights - Q2 2025 revenue reached $21 million, a 43% increase from $14.6 million in Q2 2024; gross profit was $15.9 million, up 42% year-over-year [4][5][7] - First half revenue totaled $37.7 million, a 35% increase year-over-year, with gross profit of $28.6 million, reflecting a 36% growth [5][7] - The company generated $3.6 million in cash during Q2 2025, with cash and cash equivalents amounting to $24 million as of June 30, 2025 [4][5] Operational Highlights - Sofwave's technology, SUPERB™, is FDA-cleared for various aesthetic treatments, including wrinkle reduction and muscle toning, enhancing its market position [8][9] - The company has seen significant growth in brand awareness, surpassing 1 million social media followers, which supports its market presence [3][4] - Sofwave's operational discipline and strong balance sheet are key factors in its ongoing growth strategy [3][9]

Group 1 - Sofwave Medical Ltd is an emerging leader in energy-based non-invasive aesthetic medical devices [1][2] - The company will present a corporate overview and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference from June 3-5, 2025 [1][2] - Assaf Korner, the Chief Financial Officer, will be representing the company at the conference [1] Group 2 - Sofwave Medical has developed proprietary technology called SUPERB™, which is FDA-cleared for improving facial lines, wrinkles, and skin laxity [2] - The company's Pure Impact™ module utilizes 4th generation EMS technology for muscle toning and is also FDA-cleared [2] - Sofwave's products are designed to provide effective and safe aesthetic solutions for physicians and their patients [2]

Core Insights - Sofwave Medical Ltd reported a first quarter revenue of $16.7 million, reflecting a 26% year-over-year growth, with a gross margin of 76.3% [1][8] - The company achieved a recurring revenue of $7 million, marking a 49% year-over-year increase, which now constitutes over 40% of total revenue [1][5] - Sofwave's operating loss was reported at $1 million under IFRS and $0.2 million under non-IFRS, indicating stable performance compared to the previous year [1][8] Financial Highlights - First quarter revenue reached $16.7 million, a 26% increase from $13.2 million in Q1 2024 [10] - Gross profit for the quarter was $12.7 million, up 28% year-over-year [8][10] - The company maintained a gross margin of 76.3%, slightly up from 75.2% in the same quarter last year [10] - Cash and cash equivalents stood at $20.4 million as of March 31, 2025, with cash used in the quarter amounting to $1.2 million [8] Management Commentary - CEO Louis Scafuri highlighted strong revenue growth and market leadership, attributing success to new system placements and increased procedure volumes [3] - The company achieved regulatory clearance in Japan, opening new opportunities in the APAC region [4] - The launch of the LiftHD™ body applicator generated significant market enthusiasm, reinforcing Sofwave's position in non-invasive regenerative aesthetics [4][5] Operational Highlights - Over 520,000 treatments have been conducted since the initial market approval of Sofwave's technology [9] - The company is on track to achieve operating break-even in 2025 [9] - The widespread use of GLP-1 inhibitors is driving demand for Sofwave's skin lifting and muscle toning treatments [5]